Global Aliskiren Market Size By Type (150 mg Tablet and 300 mg Tablet), By Application (Hospital and Drug Store), By Geographic Scope And Forecast

Aliskiren Market Size And Forecast

Aliskiren Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028

Key factors expected to drive the growth of the global Aliskiren Market is increasing effectiveness in controlling hypertension, aliskiren can be combined with all classes of current antihypertensive drugs, increasing the number of patients achieving blood pressure control. Moreover, an increase in government initiatives and a rise in health awareness are the factors expected to augment the global market. However, the high cost of the components of the aliskiren medicines and the production constrain the growth of the market. The Global Aliskiren Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Aliskiren Market Definition

Aliskiren (trade names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension. Direct renin inhibitors block the enzyme renin from triggering a process that helps regulate blood pressure. As a result, blood vessels relax and widen, making it easier for blood to flow through the vessels, which lowers blood pressure. Aliskiren, the first oral direct renin inhibitor, was used to treat hypertension. Renin is secreted from juxtaglomerular kidney cells, which sense changes in renal perfusion pressure, via stretch receptors within the vascular walls. The primary function of aliskiren is to eventually cause an increase in blood pressure, leading to the restoration of perfusion pressure in the kidneys. Renin-inhibitors block the activity of renin and cause vasodilatation.

Aliskiren is an antagonist to renin. Renin, the first enzyme in the renin-angiotensin-aldosterone system, plays a role in blood pressure control. It converts angiotensinogen to angiotensin I, which is then converted to angiotensin II by an angiotensin-converting enzyme. Angiotensin II is a potent vasoconstrictor that causes the blood pressure to rise. Angiotensin II also stimulates the production of aldosterone from the adrenal cortex, which causes the tubules of the kidneys to increase reabsorption of sodium, with water following, thereby increasing plasma volume, and thus blood pressure. Aliskiren is also available as a combination therapy with hydrochlorothiazide.

Global Aliskiren Market Overview

The role of aliskiren in the treatment of hypertensive diabetic patients is the major driver propelling the market growth. Standard treatments available today for treating hypertension are diuretics, angiotensin-converting enzyme inhibitors (ACEs), calcium channel blockers, α-blockers, vasodilators, and centrally acting drugs. Key factors expected to drive the growth of the global Aliskiren Market is increasing effectiveness in controlling hypertension, aliskiren can be combined with all classes of current antihypertensive drugs, increasing the number of patients achieving blood pressure control.

Moreover, an increase in government initiatives and a rise in health awareness are the factors expected to augment the global market. An increase in demand for personalized medicines, and better diagnostic facilities are likely to propel the global Aliskiren market. However, poor absorption from the gastrointestinal tract, less bioavailability, short half-life, and low potency hindered the development of these compounds. Also, the high cost of the components of the aliskiren medicines and the production constrain the growth of the market.

Global Aliskiren MarketSegmentation Analysis

The Global Aliskiren Market is segmented based on Type, Application and Geography.

Aliskiren Market, By Type

• 150 mg Tablet
• 300 mg Tablet
• Other

Based on Type, the market is bifurcated into 150 mg Tablet, 300 mg Tablets, and Other.

Aliskiren Market, By Application

• Hospital
• Drug Store
• Other

Based on the Application, the market is bifurcated into Hospital, Drug stores, and Other.

Aliskiren Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Aliskiren Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The Aliskiren Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the Aliskiren Market ecosystem results in the increasing adoption of these systems in North America.

Key Players

The “Global Aliskiren Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Noden Pharma, LGM Pharma, Cayman, Vitae-GSK, Daiichi Sankyo, Novartis, Merck-Frost, Mitsubishi-Tanabe, Takeda, and Cadila Healthcare.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

Partnerships, Collaborations and Agreements

• GlaxoSmithKline plc (GSK) and Alector announced a strategic global agreement in July 2021 to develop and commercialize two clinical-stage, possible first-in-class monoclonal antibodies (AL001 and AL101) targeted to boost progranulin (PGRN) levels. Alector’s world-class immuno-neurology expertise will be combined with GSK’s R&D focus on the immune system and human genetics, as well as its proven late-stage drug development capabilities and global footprint.

Mergers and Acquisitions

• In July 2020, private equity firm Stanley Capital announced that it had reached a definitive agreement with PDL BioPharma, Inc. to acquire Noden Pharma DAC, a leading specialized pharmaceutical company in the cardiovascular domain.

• In January 2020, Novartis AG announced that it had completed the acquisition of The Medicines Company by completing a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation, with and into the Company, with the Company surviving the merger, without a vote of the Company’s stockholders, under Section 251(h) of the Delaware General Corporation Law.

• In July 2020, Nexgen Pharma, Inc.’s formulation development and drug product contract manufacturing company has been bought by LGM Pharma. The merger combines LGM Pharma’s global experience in API procurement, distribution, and supply chain management with Nexgen Pharma’s comprehensive drug product contract development and manufacturing (CDMO) capabilities.

Product Launches and Product Expansions

• LGM Pharma announced the launch of its new Analytical Services offering in July 2021, which provides analytical testing and stability services to pharmaceutical inventors and manufacturers, as well as compounding pharmacies. The company, which already provides analytical services as part of its integrated contract development and manufacturing (CDMO) activities, is now offering its analytical services knowledge and facilities to pharmaceutical sector clients as an independent contract service.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.